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AbstrACt
Introduction Translating scientific advances in genomic 
medicine into evidence-based clinical practice is 
challenging. Studying the natural translation of genomics 
into ‘early-adopting’ health system sectors is essential. 
We will (a) examine 29 health systems (Australian and 
Melbourne Genomics Health Alliance flagships) integrating 
genomics into practice and (b) combine this learning to 
co-design and test an evidence-based generalisable toolkit 
for translating genomics into healthcare.
Methods and analysis Twenty-nine flagships integrating 
genomics into clinical settings are studied as complex 
adaptive systems to understand emergent and self-
organising behaviours among inter-related actors and 
processes. The Effectiveness–Implementation Hybrid 
approach is applied to gather information on the delivery 
and potential for real-world implementation. Stages ‘1’ 
and ‘2a’ (representing hybrid model 1) are the focus 
of this protocol. The Translation Science to Population 
Impact (TSci Impact) framework is used to study policy 
decisions and service provision, and the Theoretical 
Domains Framework (TDF) is used to understand individual 
level behavioural change; both frameworks are applied 
across stages 1 and 2a. Stage 1 synthesises interview 
data from 32 participants involved in developing the 
genomics clinical practice systems and approaches across 
five ‘demonstration-phase’ (early adopter) flagships. In 
stage 2a, stakeholders are providing quantitative and 
qualitative data on process mapping, clinical audits, 
uptake and sustainability (TSci Impact), and psychosocial 
and environmental determinants of change (TDF). Findings 
will be synthesised before codesigning an intervention 
toolkit to facilitate implementation of genomic testing. 
Study methods to simultaneously test the comparative 
effectiveness of genomic testing and the implementation 
toolkit (stage 2b), and the refined implementation toolkit 
while simply observing the genomics intervention (stage 3) 
are summarised.
Ethics and dissemination Ethical approval has been 
granted. The results will be disseminated in academic 
forums and used to refine interventions to translate 
genomics evidence into healthcare. Non-traditional 
academic dissemination methods (eg, change in guidelines 
or government policy) will also be employed.
IntroduCtIon   
Since the birth of the genomic era almost 15 
years ago,1 substantial efforts have focused 
on developing laboratory-based genomic 
sequencing capabilities and large-scale 
sequencing studies to understand the signif-
icance of sequence variation on health. In 
recent years, there has been an increasing 
focus on the application of this information 
in healthcare, for example, to improve the 
diagnosis and/or treatment of disease. The 
complex and unpredictable nature of scien-
tific advances, however, has exceeded the 
ability of health systems to establish what 
the ideal conditions, systems and behaviours 
ought to be for using genomics in complex 
healthcare settings. Rather, iterative attempts 
to apply genomics within existing (often 
pregenomics) clinical practice generate emer-
gent routines with varying levels of suitability, 
efficiency and sustainability. This ‘real’ state 
of affairs is influencing the implementation 
of genomics into routine care in the absence 
of evidence-based, ‘ideal’ approaches. A lack 
of implementation science evidence is one of 
the long list of well-documented challenges 
limiting the effective implementation of 
strengths and limitations of this study
 ► A naturalistic study of complex change for the appli-
cation of genomics into the health system.
 ► A novel methodological approach to the study of 
complexity that could be applied more widely.
 ► An approach to understanding reality and how to 
generate the ideal for implementation.
 ► A demonstration of how complexity principles can 
be incorporated into the application of behavioural 
change theory.
 ► A challenging undertaking to consolidate multiple 
components of complexity into a generalisable im-
plementation toolkit.
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genomic research into complex healthcare systems.2 A 
2017 review highlighted the lag in evidence to support 
implementation, demonstrating that very few studies to 
date have: (1) incorporated implementation science theo-
retical frameworks, sustainability measures or capacity 
building, (2) focused on macrolevel factors (eg, health 
systems, policies, financing) and (3) attempted to develop 
and evaluate evidence-based strategies for enhancing the 
implementation of genomic medicine.3 
The continuous ad hoc, emergent and self-organised 
translation modes manifesting within complex health-
care systems, as they attempt to keep pace with the 
constant stream of new genomic evidence, undoubtedly 
contribute to the challenges faced in designing protocols 
to study and test approaches to implementation. Disen-
tangling the way in which the actors in the system (eg, 
clinicians, patients, researchers, policy-makers, planners 
and decision makers) perceive, experience and natu-
rally behave under these real-world complex conditions is 
crucial for understanding the true adoption, impact and 
likely sustainability of genomic testing. It is also key to 
discovering the ideal and to designing real-world inter-
ventions to support the implementation of long-term, 
cost-effective genomics policy and practice. Furthermore, 
it has been argued that interventions to improve imple-
mentation of evidence into practice will be most effec-
tive when developed by those with local ‘expertise’ and 
tacit knowledge,4–6 but which take account of evidence 
and external expertise.7 8 In this paper, we outline a novel 
methodological approach, using complexity science, 
translation, behavioural change frameworks and codesign 
between healthcare professionals and stakeholders, and 
implementation and behavioural researchers, to study 
the integration of genomics into clinical practice as part 
of a national natural experiment and develop a generalis-
able, evidence-based toolkit for implementation.
The Australian Genomics Health Alliance (Austra-
lian Genomics) is a national network of state-based 
genomics initiatives, working together to translate 
genomic approaches into clinical practice. In 2014, 
the Melbourne Genomics Health Alliance (Melbourne 
Genomics) commenced a demonstration project, which 
laid the foundations for Australian Genomics, which was 
awarded A$25 million over 5 years (2016–2020). Together 
these alliances have placed emphasis on understanding, 
from a service level and clinical practice perspective, 
how genomic testing can be implemented in healthcare. 
Their flagship programmes are central to achieving these 
insights. A flagship is a multidisciplinary clinical group 
(e.g., medical professionals, diagnostic laboratory staff, 
genetics counsellors, etc) working together, often across 
multiple hospital sites to provide genomic testing for 
defined clinical indications according to a broad frame-
work.9 From the inception of the demonstration project 
in 2014 through to 2020, 29 flagships will be evaluating 
the use of genomics in clinical practice, across diverse 
clinical conditions (figure 1), involving specialists from at 
least 16 different health professional disciplines from up 
to 18 hospitals and 4 hospital laboratories across Australia. 
The first five Melbourne Genomics flagships have already 
undergone a formal evaluation to assess the effectiveness 
of genomic sequencing for the purposes of early detec-
tion, treatment and, where possible, prevention of major 
disease.10–13
Figure 1 Implementation research plan. AYA, adult and young adolescent; RCT, randomised controlled trial. 
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There is an immediate need to understand the emer-
gent service provision pathways and clinical processes for 
genomic testing to ensure that its impact in widespread 
practice lives up to the promise of the results of the flag-
ships12 14 established under the auspices of a research 
programme. The flagships exemplify a large-scale 
attempt to integrate genomics into everyday healthcare. 
Therefore, in addition to establishing the clinical validity 
and utility of genomics, flagships are perfectly positioned 
for a naturalistic experiment of the factors affecting the 
successful implementation of genomics into the Austra-
lian healthcare system, and for testing the impact of 
evidence-based approaches to ensure sustained, effective 
use. Each flagship represents a complex adaptive system 
(CAS)15–17; there are a number of complex features 
(eg, emergent behaviours, self-organisation, non-linear 
processes, coevolution, behaviours at the edge of chaos, 
nested systems, interconnectivity and networks, and 
simple rules which beget complex behaviours)18–21 within 
each of the participating flagships, and interactions 
between their component parts. As such, this research 
will use a complexity science lens, combined with imple-
mentation science and behavioural approaches to inves-
tigate and support the integration of genomics into the 
health system. While the flagships are distinguishable in 
form, with unique structural and cultural characteristics, 
each has been established with a common underpin-
ning framework (Australian and Melbourne Genomics). 
Therefore, studying all 29 flagships using a common 
approach is invaluable, as this permits evidence-based 
examination of their functioning and outcomes.22 It 
also provides insights into improvements in processes 
and procedures over time and enables comparison and, 
where appropriate, consolidation of findings across flag-
ships. Uniquely, then we are able to study each individual 
flagship as a CAS and also identify commonalities across 
them to produce generalisable knowledge to support the 
translation of genomics evidence into practice.
There are three broad and interacting elements of 
complexity within a flagship, or CAS (figure 2). First, clin-
ical versus implementation effectiveness: while attempting to 
test the effectiveness of genomics in the clinical setting, 
the impact of the broader health system (eg, behaviours, 
resources, logistics, politics, etc) can often distort what 
we come to understand about the success of diagnostic 
testing and subsequent treatment decisions.23–25 Deter-
mining, through rigorous research designs, how best 
to work with these health system factors to implement 
testing and treatment effectively is crucial.26 Second, 
policy decisions and service provision: for the sustained and 
evidence-based use of clinically effective genomics, it is 
important to identify which of the key resources needed 
for sound genomics practice are being funded through the 
Melbourne Genomics/Australian Genomics programme, 
and plan for the commissioning of these resources once 
programmatic funding has ended. Furthermore, organ-
isational, local area and national level policy decisions 
(relating to, eg, Medicare funding, resourcing, manage-
ment, deimplementation, etc) are likely to be affected if 
genomic practice is endorsed. Therefore, understanding 
Figure 2 Frameworks to manage complexity. TDF, Theoretical Domains Framework; TSci Impact, Translational Science to 
Population Impact.
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and planning for the management of such changes will 
be key for successful long-term implementation.9 Third, 
individual-level behavioural change: the implementation 
of genomics into clinical practice will inevitably require 
both clinical and administrative practice change.2 27
Sitting both within and across each of these three broad 
elements of complexity are key complexity principles, 
which include behaviours at the edge of chaos (high variety 
and creativity; the boundary between chaos and order), 
self-organisation (constant reorganisation of hierarchies 
and behaviours to adapt to the environment) and emer-
gence (random actions that eventually generate patterns 
which change behaviour and the system). Studying the 
emergent and self-organising behaviours within different 
flagships throughout the continuous flux will be vital for 
both identifying which of these behaviours to embed,28 
and where support through evidence-based implementa-
tion can be beneficial.20 Furthermore, while we cannot 
study the elements and principles of complexity in isola-
tion, using appropriate frameworks to understand them 
and synthesising this information in a way that helps to 
understand both successful emergent behaviours and 
gaps in practice is likely to facilitate more effective inter-
vention development.29
To address the first element of complexity (clinical 
vs implementation effectiveness), the Effectiveness–Imple-
mentation hybrid approach—a way of blending design 
components of clinical effectiveness and implementation 
research26—will be applied to the flagships across the 
5-year research programme (see figure 1). To summarise, 
first (the focus of this protocol) we will test a clinical 
intervention (in our case ‘genomic testing’) while gath-
ering information on its delivery during the effectiveness 
trial and/or on its potential for implementation in a real-
world setting (hybrid model 1); second, we will test a clin-
ical intervention and an implementation/intervention 
strategy simultaneously (hybrid model 2) and finally an 
implementation/intervention strategy will be tested while 
observing/gathering information on the clinical inter-
vention and related outcomes (hybrid model 3).
Nested within the hybrid model 1 approach, 
the Translation Science to Population Impact 
(TSci Impact)30 framework will be used to study 
the second element of complexity (policy decisions 
and service provision), and the Theoretical Domains 
Framework (TDF)8 31–35 will be used to study the third 
(individual-level behavioural change). The TSci Impact 
framework provides a systematic approach to investi-
gate the complex processes and mechanisms through 
which tested and proven interventions are inte-
grated into practice and policy in a large-scale and 
sustainable way. This framework was designed with 
complexity (or ‘systems’) science in mind,36–39 to take 
into account the complex inter-relationships between 
infrastructure and contextual influences within and 
across translation phases and promotes the study of 
complex interactions within and across implemen-
tation systems. The TSci Impact framework favours 
and facilitates the synthesis of information to under-
stand clinical trial outcomes within organisational 
settings, combined with community action research 
for rich accounts of how culture, context, local deci-
sion-making and history influence implementation of 
evidence-based practice.30
The TDF is a psychosocial and environmental 
framework of behavioural change that enables reli-
able and valid identification of psychosocial and 
environmental barriers and facilitators (eg, motiva-
tion, emotions, resources, social influences) to prac-
tice change. A key feature of the TDF includes the 
need to establish key target behaviours, and so as 
part of this work and aligning with ideas drawn from 
complexity science, we will incorporate the devel-
opment of clinical process maps to understand the 
emergent, self-organising and networking behaviours 
within and between individuals in the system, and to 
establish the ideal from the reality40 41 as these flag-
ships initiate the foundations of genomics in their 
local setting. In addition, investigating facilitators 
of behavioural change (or intuitively derived inter-
ventions42) allows for the naturalistic assessment of 
emergent and self-organised behaviours central to 
complexity theory. Finally, the TDF has previously 
been successfully used to synthesise determinants 
of behaviour and interventions collected using no 
prior framework or alternative frameworks (eg, Refs 
43–45). By studying flagships as CASs, this work aims 
to identify common features of these systems and 
networks. As such, this is an unrivalled opportunity 
to use the TDF to synthesise the complexity across 
and within flagships into a holistic implementation 
toolkit, combining knowledge of successful emergent 
behaviours with strategies to address genomics imple-
mentation problems in a targeted, standardised and 
generalisable fashion.
Aim and objectives
This paper provides an outline of a 5-year transformative 
translational change programme, and specific details for 
the initial 2-year phase to study and support the imple-
mentation of genomic testing into routine healthcare 
in clinical, organisational and policy contexts across 
Australia. The objectives of the first phase are to study 
Melbourne Genomics and Australian Genomics flagships 
to:
1. Understand the emergent and self-organising be-
haviours during the implementation of genomics into 
practice.
2. Identify successful emergent behaviours and gaps in 
practice.
3. Synthesise this information using a theoretical frame-
work.
4. Codesign, with clinicians, a foundation implementa-
tion toolkit to facilitate the translation of genomic test-
ing into clinical practice.
copyright.
 o
n
 Septem
ber 26, 2019 at Swansea University. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024681 on 5 March 2019. Downloaded from 
5Taylor N, et al. BMJ Open 2019;9:e024681. doi:10.1136/bmjopen-2018-024681
Open access
MEthods And AnAlysIs
Context
Australian Healthcare and Genomics
The Australian public health system is accessible to 
the public for free or at a lower cost through Medicare 
(funded by tax). The private system includes health service 
providers that are owned and managed privately, such 
as private hospitals, specialist medical and allied health, 
and pharmacies. The national health insurance scheme 
funded by the Australian Government currently funds 
few genetic and no genomic sequencing (whole exome/
whole genome) tests. The largest expenditure in health—
almost 40%—is on public hospital care, which includes 
some specialist genetic services and is the responsibility 
of the state governments. Genetic/genomic testing is 
funded through state government health budgets with 
availability of tests and funding varying across state. 
Governance structures exist to enable coordinated action 
and response to matters of national significance, such 
as genomics, across all Australian governments. Austra-
lian Genomics was established based on a national call 
from the National Health and Medical Research Council 
for research on the application of genomics within the 
Australian public health system. Melbourne Genomics is 
funded by the Victorian Department of Health to support 
the integration of genomics in the Victorian healthcare 
system. The implementation science component of 
this work is embedded in the overall planned research 
programme.
Flagships
Under the Melbourne Genomics and Australian 
Genomics programme of research, each of the 29 flag-
ships represents a test of the integration of genomics into 
the clinical settings within public hospital healthcare in 
parallel with usual (non-research funded) care, incor-
porating research consent processes into care processes 
delivered by genetic counsellors. The initial focus was 
on five conditions (childhood syndromes, neuropa-
thies, hereditary colorectal cancer, focal epilepsy, acute 
myeloid leukaemia), with a total of 24 additional condi-
tions planned for commencement over the following 2–3 
years (figure 1). Given this is a test of diagnostic capability 
(which may lead to more personalised treatment inter-
ventions, as opposed to being a treatment intervention 
in of itself), it is possible to administer both usual investi-
gations and the new investigation (genomic sequencing) 
to the same patient. Both the yield of the test and the 
clinical decisions resulting can be determined.46 As such, 
as opposed to a randomised controlled trial (RCT), 
which is both unnecessary and inequitable under the 
given circumstances, each flagship is incorporating an 
extended version of a comparative effectiveness research 
(CER) design,47 48 adding the assessment of clinical and 
patient utility.
The inter-related actors and processes manifesting 
as part of each flagship represent a CAS, as demon-
strated by generic flagship context examples of key CAS 
components in table 1. Flagships will, therefore, be 
studied as an individual CAS to understand the emergent 
and self-organising behaviours. In addition, commonali-
ties of integration across CASs will be studied to support 
the development of an implementation framework for 
future real-world healthcare organisations planning to 
translate genomics into practice.
research design
As part of the 5-year complexity-implementation 
science research plan, our design provides method-
ological details for the two stages used to investigate 
hybrid model 1: gathering information during the 
effectiveness trial (in this case, an extended CER) 
of a clinical intervention on its potential for imple-
mentation in a real-world situation. Stage 1, a data-re-
coding exercise, has been completed and stage 2a is 
underway, collecting data across at least a further six 
project area flagships (see figure 1). A summary of 
methods to be applied for the hybrid models 2 and 3 
are also provided. A logic model (figure 3) presents 
the activities, outputs and outcomes of stages 1 and 
2a.
Participant identification and data analysis will involve 
an expert resource group of multidisciplinary research, 
clinical and contextual expertise (table 2) for interpre-
tation and clarification of findings, consisting of experi-
enced clinicians and researchers, each bringing academic 
and/or contextual knowledge from participating sites. 
The following section contains details of participants and 
recruitment, data collection tools, research procedures 
and data analysis plan for stage 1 (post-flagship imple-
mentation) and stage 2a (pre-, during and post-flagship 
implementation).
stage 1: hybrid model 1; postimplementation (2015–2017 
timeframe)
Stage 1: participants and recruitment
Stage 1 builds on the work of the Melbourne Genomics 
evaluation team interviewing 32 clinicians across five flag-
ships in the demonstration phase. Individuals who were 
involved in developing the systems and approaches (eg, 
variant curation pipeline, variant classification frame-
works, consent forms and reporting templates for whole 
exome sequencing (WES), etc), including genetic clin-
ical specialists, and non-genetic clinical specialists who 
attended more than two multidisciplinary meetings over 
the demonstration phase, were invited to participate via 
email.
Stage 1: data collection tools
Structured interview schedule (online supplementary file 1)
The schedule was used to gather data retrospec-
tively for the Melbourne Genomics evaluation from 
stakeholders in the demonstration phase. Questions 
focused on aspects of the first implementation of 
WES into clinical practice: (1) role in the project, (2) 
experience (as a clinician or medical scientist), (3) 
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perceptions of multidisciplinary variant meetings, (4) 
views on policy decisions and procedures, (5) impact 
on their understanding and (6) factors affecting inte-
gration into practice. Probes for questions in each 
topic area are also provided for interviewers to maxi-
mise the quality of information gathered.
Evidence-based interview coding tools
While the data from these interviews was originally 
used to obtain insights into the ‘what’ of the flagship, 
additional tools have been selected to code these inter-
views from an evidence-based, behavioural perspective. 
More specifically, TDF coding and behavioural change 
Table 1 Flagships as complex adaptive system (CAS)
CAS component Flagship example
A large number of elements 
which interact dynamically
Key flagship elements include patients (and their own influences outside the official 
healthcare system), staff (eg, different professions, hierarchies and approaches to decision-
making), locations (multiple sites, laboratories and clinicians not co-located), resources (time, 
money, etc), organisations, leadership, clinical processes, research processes—all of which 
will interact.
Any element in the system is 
affected by and affects several 
other systems
For example, the flagship is operating within the broader CAS—incorporating new genomic 
investigations and procedures within existing patient care pathways, and evaluating the 
process and outcomes. This involves an iterative process affected by (and impacting) 
pre-existing clinical and laboratory systems for patient assessment, decision-making and 
patient consent for the genetic diagnostic process, sign off, counselling, sampling, transit, 
batching, sequencing, computational access, analysis, interpretation, reporting, etc. Different 
professions interact throughout this process to make a final decision.
Non-linear interactions, so small 
changes can have large effects
While the pathway that must be taken to complete the process for any given genetic 
test is generally linear, the interactions within and between each stage are non-linear (eg, 
within the decision about which test is most appropriate for a patient, there is formal and 
informal discussion between clinicians and clinical geneticists about the appropriateness of 
genomic testing and the area of focus required) and iterative (eg, first analysis of the results 
may prompt re-examination of the clinical picture and alter decisions about the focus of 
the genomic analysis). Furthermore, the exploratory nature of flagships under a research 
programme introduces further ambiguity (eg, around future funding or clinical utility of 
genomic testing in that condition).
Openness, so it may be difficult 
to define system boundaries
As a broad example, the funding of resources for genomic sequencing within participating 
health services overlaps with existing government-commissioned resources for a flagship. 
As a research programme operating in a real-world health system, this scenario may affect 
clinical decision-making for patients due to boundaries stipulated in research protocols 
within which clinicians must operate.
A more specific example includes the uncertainty held regarding whether or not and 
when to communicate incidental findings to patients, and the ethical decision-making 
behind undertaking clinical re-analysis of previously collected samples as new genes are 
discovered.
While new knowledge for patient diagnosis and treatment is a clear benefit from the 
continuously evolving basic and clinical research perspective, impact on practice can 
involve periods of time where there is more ambiguity and uncertainty about what is best 
for patients. Policies help to define this but generate boundaries, which can be frustrating, 
particularly if they are not up to date with new evidence. This can be where deviations arise 
and new, informal, unrecorded patterns emerge.
A constant flow of energy to 
maintain the organisation of the 
system
Flagships require all those involved in completing the diagnostic process to be on board, but 
as with any health system, perceptions of value of different parts of the process, including 
the outcome, can vary and evolve among both patients and professionals. This can affect 
the willingness to participate and the flow of energy in the system.
A history whereby the past helps 
to shape present behaviour
The involvement of genetics and genetic specialists in patient care differs across flagships. 
The extent of this past involvement, and the nature of the relationships between disciplines 
and different locations, influences the introduction of genomics, specifically the protocols 
and procedures, as well as dynamics within a flagship.
Elements in the system are not 
aware of the behaviour of the 
system as a whole and respond 
only to what is available or 
known locally
For example, flagships are operating as externally funded entities within the existing 
healthcare system—individuals are well aware of the need for funding but not so much the 
need to disinvest; they are also primarily concerned with the operations and needs of their 
own flagship(s). There are also other flagships as well as the health system as a whole, which 
have different circumstances, and are having an impact/being impacted on.
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techniques (BCTs) guidance,31–33 and agreed definitions 
of the TDF in the genomic context (see table 3)49 was 
used to: (1) identify behavioural areas for change, (2) 
group key barriers and enablers to implementation of 
genomic sequencing according to theoretical domains 
of behavioural change and (3) capture any BCTs32 repre-
sented in any existing or new intuitive intervention strate-
gies described by participants.
Stage 1 procedures
Two behavioural researchers independently recoded 
10 of the Melbourne Genomic evaluation interviews 
according to the TDF, then compared findings for inter-
rater reliability. The remaining 22 interviews are being 
recoded by one researcher. Where there are differences 
or queries, a TDF expert is being used to advise on the 
appropriate coding. Once complete, the recoded data 
will be discussed with the expert resource group for sense 
checking.
Stage 1 data analysis plan
Interview data has been audio recorded, fully transcribed 
and entered into NVivo 11 (QSR International, 2015). 
Analysis will vary dependent on the interview intent. 
The TDF reanalysis of the Melbourne Genomic data will 
establish target behaviour areas and key barriers to focus 
on in subsequent interviews. The recoding process using 
the TDF will also allow identification of psychosocial 
domains within each target area. Domains not identified 
will be included in the stage 2a clinical process interviews 
to identify if they have relevance within each target area.
stage 2a: hybrid model 1 pre-, during and postimplementation 
(2018–2019 timeframe)
Stage 2a: participants and recruitment
Two key participant groups, each of which will be recruited 
for one or more of the different interviews and focus 
groups will be drawn from the Australian and Melbourne 
Genomic Flagships. Given the focus on service provision 
and policy, and clinical process aspects of implemen-
tation, the target groups for participation represented 
these areas:
(1) Service provision pathway participants: A total 
of 37 decision-makers and stakeholders (both clin-
ical and administrative, playing a key role in either 
flagship leadership, funding and financing strategies, 
genomic testing characteristics and costs, organisa-
tional and community factors or policy) who have 
been identified as fulfilling the inclusion criteria 
Figure 3 Logic model. TDF, Theoretical Domains Framework.
Table 2 Expert resource group expertise
Expert identifier 
number
Genetic clinical 
expertise
Non-genetic 
clinical expertise
Laboratory 
expertise
Genetic operational
knowledge
Implementation science 
expertise
1 X X
2 X X
3 X X
4 X
5 X X
6 X X
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across the flagships and states will be invited to partic-
ipate in an interview.
(2) Clinical process delivery participants: A total of 27 
clinical non-genetics medical specialists (eg, oncologists, 
neurologists) who have been identified as fulfilling the 
inclusion criteria across the flagships and states will be 
invited to participate in an interview.
Across both participant groups, up to 12 people will 
be invited to participate in a focus group to be held in 
each state (ie, Victoria, Tasmania, New South Wales, 
Table 3 Recoding guide
TDF domain TDF domain definition (Cane et al, 2012) Definition in context
Knowledge An awareness of the existence of something Clinicians’ actual awareness and understanding 
(through education/training) of the principles and 
process of offering genetic testing in clinical practice
Skills An ability or proficiency acquired though practice Clinicians’ actual physical and psychological ability 
or proficiency acquired through actual practice 
(as opposed to education/training—skills cannot 
be acquired though education) to make decisions 
whether or not to offer genetic testing in practice
Memory, attention 
and decision 
processes
The ability to retain information focus selectively 
on aspects of the environment and choose 
between two or more alternatives
Clinicians’ ability to remember to consider genetic 
testing alongside other interventions for health risk 
identification, diagnosis, management and therapy
Behavioural 
regulation
Anything aimed at managing or changing 
objectively observed or measured actions
Clinicians’ self-created or self-imposed regulation to 
help make decisions about offering genetic tests
Social influences Those interpersonal processes that can cause 
individuals to change their thoughts, feelings or 
behaviours
Interpersonal interactions between professionals 
that can influence clinicians’ thoughts, feelings or 
behaviours (ie, anything in motivation) regarding 
offering genetic testing
Environmental 
context and 
resources
Any circumstance of a person’s situation or 
environment that discourages or encourages the 
development of skills and abilities independence, 
social competence and adaptive behaviour
Any external circumstance of a clinicians’ situation or 
environment that clinicians consider discourages or 
encourages them to offer genetic testing in practice, 
including impacting the development of capability, 
motivation or social opportunity to offer genetic 
testing
Social/professional 
role and identity
A coherent set of behaviours and displayed 
personal qualities of an individual in a social or 
work setting
Clinicians’ perceived professional role and identity in 
relation to offering genetic tests
Beliefs about 
capabilities
Acceptance of the truth, reality or validity about 
an ability, talent or facility that a person can put to 
constructive use
Clinicians’ perception about their own capability to 
consider genetic testing (terms used in literature: 
confidence, comfort, control)
Optimism The confidence that things will happen for the 
best or that desired goals will be attained
Clinicians’ optimism or pessimism that genetic testing 
will be appropriately integrated into clinical practice 
and will improve healthcare generally
Beliefs about 
consequences
Acceptance of the truth, reality or validity about 
outcomes of a behaviour in a given situation
Clinicians’ perceptions about the value of offering 
genetic testing in clinical practice—whether it is 
worthwhile in that it will improve patient outcomes in 
their own practice (term used in literature: attitude)
Intentions A conscious decision to perform a behaviour or a 
resolve to act in a certain way
Clinicians’ intentions to consider genetic testing
Goals Mental representations of outcomes or end states 
that an individual wants to achieve
Whether clinicians offering genetic testing is a priority 
within their practice
Reinforcement Increasing the probability of a response 
by arranging a dependent relationship, or 
contingency, between the response and a given 
stimulus
Incentives, rewards, sanctions, reinforcement at any 
level (eg, patient satisfaction, better client health, 
economic incentives) that encourage or increase 
clinicians’ decisions to offer genetic testing
Emotion A complex reaction pattern, involving experiential, 
behavioural and physiological elements, by which 
the individual attempts to deal with a personally 
significant matter
Clinicians’ feelings when they consider genetic testing
TDF, Theoretical Domains Framework. 
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South Australia and Western Australia). The partic-
ipants invited will depend on the findings from the 
individual interviews.
Selection criteria will be established (see table 4) to 
facilitate recruitment of expert informers for inter-
view based on their experiences of implementation of 
genomics in their organisation. Individuals fulfilling 
the inclusion criteria will be identified using the 
knowledge of the expert resource group. Recruitment 
for individual interviews and focus groups will consist 
of multiple strategies, including making use of the 
networks of the expert resource group to facilitate 
research participant contact; individual emails will be 
sent. Interview times and locations will be arranged 
based on convenience for interviewees to enhance the 
likelihood of participation.
Stage 2a: data collection tools
A process mapping guide (figure 4), a clinical audit, two 
semistructured interview schedules (online supple-
mentary files 2 and 3) and an intervention codesign 
guide (online supplementary file 4) will be used to 
gather qualitative and quantitative data.
Clinical process mapping template
Informed by stage 1 interviews and the expert resource 
group, the template (figure 4) will present an outline of 
the WES process to participants, covering: (1) the patient 
presenting at clinic, (2) the process for analysis and (3) 
communication of results to patient. Each section will 
act as a prompt to clarify processes and an opportunity 
for participants to amend the outline process map in 
relation to processes specific to their clinical area (eg, 
childhood syndromes, cancer, etc) with regards to where 
processes begin and end, tasks involved, who contributes, 
who is affected and where glitches occur in the system. 
This will enhance understanding as to how current clin-
ical processes have emerged and are currently operating 
from a pre-, during, and/or postimplementation of WES 
perspective. Furthermore, emergent barriers to imple-
mentation, and any current or suggested intervention 
strategies captured as part of these discussions will be 
noted.
Clinical practice audit tools
Collects information about recorded practice prior to, 
during and postimplementation of genomic sequencing. 
Audit data will be collected to reflect key components of 
the process map to demonstrate where gaps, blocks and 
problems exist in the system. For example, date stamped 
data of the detailed patient journey from referral into 
WES, test ordering and interpretation, and communica-
tion of results to patients will be collected and matched to 
specific process map steps.
Clinical processes interview schedule
Collects views from non-genetic clinical specialists on 
the early, mid- and late phases of implementing a flag-
ship. The interview schedule, informed by the results of 
the stage 1 TDF-coded interviews and informed by the 
Melbourne Genomics Community Advisory Group, is 
framed according to relevant TDF domains. Questions 
enquire about the same three key behavioural areas 
examined in the process map: (1) the patient presenting 
Table 4 Stage 2a interview inclusion criteria
Service provision participant inclusion criteria
Inclusion criteria Justification
Strategic decision-makers Involved with direction and funding for services including 
genomics
Service level managers or above (eg, CEO) Will have either signed off on a flagship application, have a 
flagship running in their organisation or be managing a flagship
Senior clinical geneticists Will have an overview of genomic testing in more than one 
flagship across clinical genetics and medical specialities
Flagship involvement from any phase of implementation To gather views across the implementation journey
Draw participants from a cross-section of locations To ensure a broad representation of views
Clinical processes participant inclusion criteria
Inclusion criteria Justification
Medical specialists (excluding clinical geneticists) Focus of study is mainstream tertiary implementation in the 
long term
AND working within a flagship Practitioner will have genomics knowledge
Flagship involvement from any phase of implementation To gather views across the implementation journey
Working in Australian Genomics or Melbourne Genomics 
flagship
These are the sites for the genomic work
Draw participants from a cross-section of locations To ensure a broad representation of views
CEO, chief executive officer.
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at clinic, (2) the process for analysis and (3) communi-
cation of results to patient. For example, in the third 
behavioural area, ‘communicating results,’ the question 
relating to the ‘emotion’ TDF domain is When results are 
uncertain how do you feel about feeding this back to the patient? 
And for the ‘optimism’ TDF domain,What gives you confi-
dence that this process is being handled well?.
Service provision interview schedule
Collects views from key decision-makers and stakeholders 
on factors influencing the uptake of genomic medicine 
at different phases of implementation, and on preparing 
for the transition from flagship to ordinary clinical 
service status for the sustainability of genomic testing 
once programmatic funding has ended. Areas identified 
Figure 4 Process mapping guide.
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for exploration at interview were debated with the expert 
resource group, with Spoth et al’s (2013) TSci Impact 
framework being favoured for investigating translation 
phases of preadoption, adoption, implementation and 
sustainability from a service provision and policy perspec-
tive. Some interviewees will need to reflect back on the 
early phases of preadoption, while others will be in the 
translation function so will be able to draw on current 
experiences. To facilitate interview participants’ focus 
on the phase under discussion, a graphic has been devel-
oped to use at interview (see figure 5). Working through 
the translation phases, questions focus on the following 
topic areas: (1) gaining clinical genomic knowledge; (2) 
influences on the decision to adopt; (3) the impact of the 
organisational setting and health system and (4) influ-
ences on sustainability including disinvestment.
Barrier verification and intervention strategies’ codesign guide
This two-phase guide will present a summary of infor-
mation gathered in the process mapping interviews 
and audit data cross-matching exercise, and the clinical 
processes and service provision interviews (across the 
respective associated behavioural/topic areas covered), 
synthesised according to the TDF domains and BCTs. In 
phase 1, prompts and materials (online supplementary 
file 4) will be provided to encourage discussion about 
the barriers list presented, to elicit information about 
any additional barriers and to narrow down a list of key 
barriers to focus on. In phase 2b, a provisional list of inter-
vention strategies that could be used to address those 
barriers will be presented. Guidance will be provided 
to facilitate the design of any new interventions using 
BCTs. A matrix will be provided to facilitate ranking of 
the interventions according to feasibility and impact on 
the associated barriers and subsequent behavioural areas 
(online supplementary file 4).
Stage 2a: procedures for interviews and prefocus group data 
synthesis
Generic interview procedure
Before commencing all interviews, the interviewer (SB) 
will go over consent procedures, provide a Participant 
Information Sheet, obtain permission to record the inter-
view, and then record verbal consent. The interview, which 
is likely to last around 60 min, will be recorded using a 
digital recorder, then transcribed. All participants will be 
assigned a code (eg, Participant CP/SL 1, 2, 3 etc) and 
interviewees will only be identified via these codes. Digital 
audio files will be imported into the software Nvivo 11 
(QSR International, 2015) to facilitate analysis.
Process mapping interview and integration with audit data
Hard copies of outline process maps (figure 4) will be 
handed to clinical process interviewees to prompt discus-
sion about the process for that particular clinical area (eg, 
paediatric rare diseases, cancer, etc), to inform refine-
ments to the map and to elicit information about barriers 
and facilitators to undertaking the process. These data 
will be transferred into Microsoft Visio software; partici-
pants will be contacted via email and asked to review their 
revised map and suggest any refinements. The provisional 
list of audit data collection variables will be finalised on 
the basis of the process map, collected via organisation 
electronic and/or paper-based patient records, with rele-
vant information cross-matched to specific parts of the 
process. The outputs of this stage of the project will be: 
(a) a detailed, visual and data-verified outline of clinical 
area-specific processes for genomic testing pathways, (b) 
a data-driven method of identifying key gaps or imper-
fections in the process and (c) a set of emergent barriers 
and existing or potential interventions for improvement 
of processes.
Figure 5 Service provision interview translation phases graphic.
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Clinical process
The TDF-based interview schedule (see online supple-
mentary file 2) will be used with clinical process inter-
viewees to discuss, using the lens of a psychosocial and 
environmental theoretical framework, barriers and facili-
tators to implementation of genomics in clinical practice, 
and to elicit information about existing or potential inter-
ventions for improvement. The outputs from this data 
collection procedure will be information on TDF-based 
barriers and emergent interventions.
Service provision and policy interviews
The TSci Impact framework-based interview schedule 
(see online supplementary file 3) will be used with service 
provision and policy interviewees to discuss factors influ-
encing the uptake of genomic medicine at different 
phases of implementation using the lens of translating 
science into policy and services perspective. Outputs here 
will include data on policy and service provider factors 
affecting implementation pathway, and information on 
emergent barriers and interventions.
Stage 2a: data-informed focus group schedule development and 
data collection
Preparation of focus group materials through synthesis of 
interview data
Data from the stage 1 recoding, and stage 2a process 
mapping/audit data, clinical process and service provi-
sion interviews will be synthesised by the expert resource 
group in preparation for the focus groups (online supple-
mentary file 4). For both clinical processes and service 
provision and policy, summary tables will be developed 
with a set of key target areas for improvement, context-spe-
cific barriers and corresponding TDF domains, emergent 
intervention strategies alongside corresponding BCTs, 
and instructions for ranking the likely impact and feasi-
bility of intervention strategies. Key barriers from all the 
clinical specialties will be combined to develop generalis-
able interventions.
Focus groups (two phases)
 The synthesised data will be used with a multidis-
ciplinary group of clinicians and service provision/
policy decision-makers to verify barriers and code-
sign intervention strategies using both emergent 
and evidence-based behavioural change approaches. 
Using the materials from the data synthesis exercise, 
the discussion in phase 1 will be used to verify and 
identify any additional barriers and to rank barriers 
according to the level of impact on behavioural areas. 
Phase 2 discussions, informed by phase 1 and with a 
provisional list of intervention strategies, will be used 
to codesign interventions to address the high impact 
barriers to implementation using the most feasible and 
likely impactful intervention strategies. A hypothetical 
example mapping how the flow of data from interviews 
in stage 2a will flow to intervention design is provided 
in online supplementary file 4.
Stage 2a: development of foundation implementation toolkit
A draft implementation toolkit will be developed using 
the recorded and written focus group data to present 
intervention strategies to address key barriers to clin-
ical processes and service provision implementation 
of genomics evidence into practice. Both interview/
focus group participants, the expert resource group and 
the Consumer Advisory groups of the Australian and 
Melbourne Genomics Health Alliances will be invited to 
review the contents of the first iteration of the genomics 
implementation toolkit.
Stage 2a: data analysis plan
Data synthesis prior to focus groups
Initial synthesis will be undertaken by SB. The process 
mapping and clinical audit data will be analysed for data 
on processes, individual interactions, data-driven gaps 
(within the four target areas) and also emergent barriers 
and interventions. Clinical audit data analysis will consist 
of computation of descriptive statistics, proportions and 
timeframes between steps in clinical processes. This infor-
mation, where available, will be matched to the relevant 
steps in the process map to highlight gaps or bottlenecks. 
Clinical process interview data will be analysed deduc-
tively using the TDF to identify key domains representing 
barriers to change, and appropriate BCTs will be mapped 
to these domains as an evidence-based approach to inter-
vention strategy development.31–33 Service provision 
interviews will be thematically analysed and used to iden-
tify key areas for the development of service provision 
planning. These data will also be analysed according to 
the TDF and BCTs to facilitate the combined approach 
to developing clinical process and service provision inter-
ventions for the two-phase focus groups. These processes, 
barriers, and intervention data within the target areas will 
be collated and shared with the expert resource group. 
The expert resource group will analyse these data and 
develop the focus group materials to demonstrate key 
reported barriers to and suggested intervention strategies 
for effective implementation of genomics in practice.
Focus group analysis
Individual focus group analysis will be undertaken using 
the TDF and BCTs to identify validated and new barriers 
to change, and BCTs, respectively. Results of this exercise 
from each focus group will be provisionally combined to 
generate the first iteration of the genomics implementa-
tion toolkit.
Patient and public involvement
The stage 2a clinical processes interview schedule is 
informed by the results of the stage 1 TDF-coded inter-
views. Patient and public involvement was sought from 
the Melbourne Genomics Community Advisory Group. 
Through a facilitated discussion, the group identified 
their priority areas for implementation and sustain-
able delivery of genomics (eg, ‘How do you manage 
patient expectation?’), which were incorporated into the 
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interview schedule. Findings from data collection will 
be discussed with the Consumer Advisory groups of the 
Australian and Melbourne Genomics Health Alliances 
and they will be invited to review the contents of the first 
iteration of the genomics implementation toolkit.
EthICs And dIssEMInAtIon
Ethical approval for this study has been granted by 
Melbourne Health HREC on 3 November 2017, as an 
amendment to the Melbourne Genomics approved 
protocol number: HREC/13/MH/326. Governance 
approval has been provided by Australian Genomics and 
Melbourne Genomics participating institutions.
Dissemination of results will be undertaken through 
traditional academic forums, but also through the infor-
mation generated through this research being used to 
refine and apply evidence-based and pragmatic interven-
tions into health systems for the translation of genomics 
into practice. In addition, the Translational Science Bene-
fits Model (TSBM)50 will be used to further understand 
the actual and potential value of genomics to society, and 
open up further opportunities for dissemination.
dIsCussIon
In Australia, the majority of clinical genomic sequencing is 
currently funded through research activities. Melbourne 
Genomics and Australian Genomics bridge the gap 
between research and established clinical practice. They 
represent systematic national and state-based efforts to 
integrate genomics into everyday healthcare. For the 
majority of flagships and health professionals working 
within them—many of whom are not experts in the field 
of genomics— this is the first time genomic sequencing 
tests have been available to them ‘in real time’. While they 
are making efforts to incorporate this into their practice, 
it is impossible for clinicians—genetic and non-genetic 
alike—to know what the ‘ideal’ is yet. Therefore, no prec-
edent exists for effectively implementing genomics into 
practice for numerous clinical conditions across different 
contexts. The diversity of health professional disciplines, 
healthcare organisations, clinical indications partici-
pating across the 29 flagships (all of which are at different 
stages of implementation and involve a mixture of early, 
mid and late adopters)will realise the ultimate goal of this 
work: to establish the ‘ideal’ and develop a generalisable 
model of implementation that future organisations can 
apply and tailor to their local contexts. The planned work 
for the remainder of this project will determine the finer 
details of this model, but the vision is for an interactive, 
theoretically underpinned, continuously refined toolkit 
informed by real-world data. This approach will enable 
diverse healthcare organisations at any stage of imple-
mentation to tailor their context-driven approach based 
on tried and tested intervention strategies used to address 
key challenges experienced by others.
The detailed methods for the current body of work—
stages 1 and 2a, forming the foundations of this trans-
formative translational change programme, have been 
presented here. Future work will then build on data 
and strategies developed as part of hybrid model 1. To 
summarise, hybrid model 2 (see figure 1—stage 2b; 2019–
2020 timeframe) will consist of a simultaneous test of the 
clinical effectiveness of genomic sequencing and the 
implementation toolkit concurrently26 in new flagships. 
Quantitative and qualitative measures for assessing imple-
mentation effectiveness will be explored and developed51 
(figure 1). A formal, concurrent test of the clinical effec-
tiveness of genomics and the implementation toolkit will 
be undertaken, allowing for a detailed analysis, distinction 
and explanation of the complex factors associated with 
clinical versus implementation effectiveness. During this 
stage (and stage 3), the Standards for Reporting Imple-
mentation Studies Checklist52 will be used to support the 
planning and reporting of intervention strategies and 
implementation effectiveness. These findings will be used 
to further refine the toolkit.
The final stage (hybrid model 3) (see figure 1 —stage 
3; 2020–2021 timeframe) will focus on testing the refined 
implementation toolkit while simply observing the 
genomics intervention and related outcomes.26 Consoli-
dating the earlier work, this stage will include real-world 
Table 5 Translational Science Benefits Model applied to genomics context and implementation outcomes
TSBM domain Potential benefit TSBM indicator
Potential Proctor et al 
(2017) implementation 
outcome
Clinical and 
medical
Streamlining processes Development of procedural 
guidelines
Acceptability
Adoption
Community and 
public health
Saving patients from unnecessary 
procedures
Reduces diagnostic odyssey
Decrease non-essential tests 
ordered
Time to diagnosis
Appropriateness
Fidelity
Feasibility
Economic 
benefits
Increase in genomic testing and 
reduction in non-essential testing
Tests ordered Implementation cost
Policy and 
legislation
Disinvest in unnecessary procedures Change in government and 
organisation policies to support 
increased use of genomic testing
Penetration
Sustainability
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testing of the implementation toolkit (eg, RCT; stepped 
wedge trial) against a comparison, and/or with a stan-
dard roll out, with the aim of informing state and national 
policy and decision-making. Following recommendations 
by Curran and colleagues,26 summative outcomes— 
including adoption/uptake of the clinical intervention, 
process measures and quality measures—will be assessed 
using data collection tools and approaches specifically 
designed for measuring implementation outcomes 
developed in stage 2b51 (see figure 1). Furthermore, 
these outcomes will be mapped against the TSBM50 to 
demonstrate implementation outcomes across clinical, 
community, economy and policy contexts—a hypothet-
ical example of this is provided in table 5.
This study is not without limitations. First, recoding 
interviews undertaken in 2015 as part of stage 1 may not 
remain entirely representative of stakeholder perceptions 
that exist at present. However, these views may be repre-
sentative of individuals based at new sites which have not 
yet been exposed to genomic sequencing. Further to this, 
interview data from stage 1 are being coded retrospec-
tively using the TDF. While this will allow for identification 
of the issues most salient to interviewees, using the TDF to 
inform the interview schedule may have elicited informa-
tion about barriers that are less spontaneously reported.53 
Moving forward beyond the original interviews, however, 
interview schedules have been designed based on the 
TDF; this will not only enhance the evidence based by 
which information is collected but may also allow for a 
comparison of answers provided by participants using 
both interview approaches. Finally, the study is based 
on the implementation of genomics into the Australian 
health system which, like any health system globally, has a 
unique composition and combination of idiosyncrasies in 
terms of infrastructure and funding. However, the varied 
nature of the Australian system (eg, the combined private/
public system) has its benefits in that it bares some resem-
blance with countries that have publicly funded (eg, UK, 
Canada), but also with those operating insurance-based 
funding (eg, Germany, the USA). The novel approach 
taken here aims to enable the ability to identify gener-
alisable interventions for addressing common challenges 
across contexts.
This is the first nationally based real-world study 
of a large cohort of CASs, deliberately attempting to 
integrate genomics into a real-world, complex health 
system. To study and support implementation of a tech-
nology with far-reaching consequences but currently 
limited evidence base, we have developed a novel meth-
odological approach consisting of complexity science, 
policy and service provision, individual level behavioural 
change frameworks and progressively more rigorous 
research designs. Disentangling clinical research 
processes from those which support adoption of a new 
standard of care, our work will provide streamlined 
recommendations for future healthcare organisations 
planning to translate genomics into their health system. 
This methodology may be one that lends itself to study 
and support the adoption of other potentially ‘paradigm 
shifting’ technologies.
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